← Back to Search

Radiation Therapy

1 for Huntington's Disease

Phase 1
Waitlist Available
Led By Ken Nedd, M.D.
Research Sponsored by GAAD Medical Research Institute Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
People with HD
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances. This study will investigate the use of far infrared radiation for control, management and treatment of HD.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment of people with HD
Secondary outcome measures
Rehabilitation of people with HD

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Find a Location

Who is running the clinical trial?

GAAD Medical Research Institute Inc.Lead Sponsor
21 Previous Clinical Trials
90 Total Patients Enrolled
Ken Nedd, M.D.Principal InvestigatorGAAD Medical Research Institute Inc.
19 Previous Clinical Trials
88 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025